EARNINGS BRIEF

IBM Stock Drops 6% Despite Earnings Beat… BofA Maintains Buy with Conditions

IBM beat Q1 estimates with $15.9B revenue and $1.91 EPS, but shares plunged 6%. Bank of America cited margin guidance disappointment and consulting weakness while maintaining a $300 price target with Buy rating.

Justin·April 24, 2026·4 min read

AI Summary

IBM beat Q1 revenue and EPS estimates but the stock fell 6%. Q2 margin guidance disappointed, software growth showed heavy reliance on acquisition effects, and consulting margin compression added pressure. BofA maintained Buy with a $300 target. Key questions going forward: Confluent integration execution and organic software growth. IBM Z mainframe revenue surged 51%. At current prices, BofA's target implies ~18% upside.

IBM beat expectations on nearly every Q1 metric, yet shares tumbled over 6%. Bank of America identified three key concerns: disappointing margin guidance, software growth dependent on acquisition effects, and consulting margin compression, while maintaining a $300 price target with Buy rating.

Headline Beat, But Stock Drops 6%

IBM (IBM) reported Q1 2026 results on April 22nd that broadly exceeded market expectations. Revenue rose 9.5% year-over-year to $15.92 billion, beating consensus ($15.71 billion), while adjusted EPS of $1.91 surpassed estimates ($1.81) by 5.5%.

Revenue: $15.92B (+9.5% YoY, vs. $15.71B estimate)
EPS: $1.91 (vs. $1.81 estimate, +5.5%)
Software: $7.05B (+11%)
Infrastructure: $3.33B (+15%), IBM Z mainframe +51%
Operating margin: 11.7% (improved 1.7pp from 10% prior year)

Management reaffirmed annual guidance of 5%+ constant currency revenue growth and $1 billion increase in free cash flow. However, shares initially dropped to $235 before recovering partially to around $255.

BofA Identifies Three Factors Behind Stock Decline

Bank of America analyst Wamsi Mohan identified three underlying factors that unsettled markets despite the headline beats.

Q2 pre-tax income guidance implied only 50bp margin improvement, well below market expectations of 75bp.
While software constant currency growth guidance was raised from 'teens' to 'above 10%', much of the improvement stems from the Confluent acquisition rather than organic growth.
Consulting segment margins compressed slightly, reigniting concerns that AI demand has yet to translate into performance improvements in this division.

No single factor is fatal, but the combination of all three was sufficient to dampen near-term expectations.
BofA analyst Wamsi Mohan

"Confluent Integration Execution Next Key Variable"

BofA maintained its Buy rating and $300 price target, stating that the long-term investment thesis remains intact. The firm cited IBM's ongoing shift toward higher-margin software, strong free cash flow improvement, and quantum computing as a long-term value option.

Near-term focus centers on Confluent integration execution. IBM's $11.6 billion acquisition of Confluent's data streaming technology holds an important position in enterprise AI infrastructure, but markets want to see this translate into organic software growth beyond acquisition effects.

BofA left open the possibility of additional M&A if software valuations become attractive in the second half, but emphasized that the immediate priority is proving execution capability with existing assets. The $300 price target represents approximately 18% upside from current levels (around $255).